{"organizations": [], "uuid": "842d12f51c2e42d4a59768020021f9271052a1d2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180522.html", "section_title": "Archive News &amp; Video for Tuesday, 22 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-sublimity-therapeutics-completed-6/brief-sublimity-therapeutics-completed-64-mln-financing-to-further-development-of-new-oral-ulcerative-colitis-drug-candidate-idUSFWN1ST0BN", "country": "US", "domain_rank": 408, "title": "BRIEF-Sublimity Therapeutics - Completed $64 Mln Financing To Further Development Of New Oral Ulcerative Colitis Drug Candidate", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.473, "site_type": "news", "published": "2018-05-22T18:24:00.000+03:00", "replies_count": 0, "uuid": "842d12f51c2e42d4a59768020021f9271052a1d2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-sublimity-therapeutics-completed-6/brief-sublimity-therapeutics-completed-64-mln-financing-to-further-development-of-new-oral-ulcerative-colitis-drug-candidate-idUSFWN1ST0BN", "ord_in_thread": 0, "title": "BRIEF-Sublimity Therapeutics - Completed $64 Mln Financing To Further Development Of New Oral Ulcerative Colitis Drug Candidate", "locations": [], "entities": {"persons": [], "locations": [{"name": "longitude", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "orbimed", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 22 (Reuters) -\n* SUBLIMITY THERAPEUTICS - COMPLETED $64 MILLION FINANCING TO FURTHER DEVELOPMENT OF STI-0529 FOR TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS\n* SUBLIMITY THERAPEUTICS SAYS FINANCING WAS CO-LED BY ORBIMED AND LONGITUDE CAPITAL WITH PARTICIPATION FROM HBM HEALTHCARE INVESTMENTS. Source text for Eikon:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-22T18:24:00.000+03:00", "crawled": "2018-05-23T15:01:35.034+03:00", "highlightTitle": ""}